{"id":"NCT01708902","sponsor":"Boehringer Ingelheim","briefTitle":"Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients","officialTitle":"A Phase III Randomised, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy and Safety of Twice Daily Administration of the Fix Dose Combination of Linagliptin 2.5 mg + Metformin 500 mg, or of Linagliptin 2.5 mg + Metformin 1000 mg, With the Individual Components of Metformin (500 mg or 1000 mg, Twice Daily), and Linagliptin (5.0 mg, Once Daily) Over 24 Weeks in Treatment naïve Type 2 Diabetic Patients With Insufficient Glycaemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2012-10-17","resultsPosted":"2015-04-24","lastUpdate":"2015-04-24"},"enrollment":876,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"linagliptin2.5mg/metformin1000mg","otherNames":[]},{"type":"DRUG","name":"linagliptin2.5mg/metformin1000mg","otherNames":[]},{"type":"DRUG","name":"linagliptin 5mg","otherNames":[]},{"type":"DRUG","name":"Metformin 500mg","otherNames":[]},{"type":"DRUG","name":"linagliptin2.5mg/metformin500mg","otherNames":[]},{"type":"DRUG","name":"linagliptin2.5mg/metformin500mg","otherNames":[]},{"type":"DRUG","name":"linagliptin 5mg","otherNames":[]},{"type":"DRUG","name":"Metformin 1000mg","otherNames":[]}],"arms":[{"label":"linagliptin2.5mg / metformin500mg BID","type":"EXPERIMENTAL"},{"label":"linagliptin2.5mg / metformin1000mg BID","type":"EXPERIMENTAL"},{"label":"metformin 500mg BID","type":"ACTIVE_COMPARATOR"},{"label":"metformin 1000mg BID","type":"ACTIVE_COMPARATOR"},{"label":"linagliptin 5 mg QD","type":"ACTIVE_COMPARATOR"}],"summary":"Reduced factorial design study with 24 week randomized treatment of initial combination therapy with linagliptin and metformin in T2DM patients","primaryOutcome":{"measure":"The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group","timeFrame":"Baseline and week 24","effectByArm":[{"arm":"Main: Linagliptin 5mg QD","deltaMin":-1.29,"sd":0.08},{"arm":"Main: Metformin 500mg BID","deltaMin":-1.64,"sd":0.08},{"arm":"Main: Metformin 1000mg BID","deltaMin":-2.07,"sd":0.08},{"arm":"Main: Linagliptin 2.5mg / Metformin 500mg BID","deltaMin":-2.15,"sd":0.08},{"arm":"Main: Linagliptin 2.5mg / Metformin 1000mg BID","deltaMin":-2.29,"sd":0.08}],"pValues":[{"comp":"OG002 vs OG004","p":"0.0587"},{"comp":"OG000 vs OG004","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":56,"countries":["China","Malaysia","Philippines","Vietnam"]},"refs":{"pmids":["32328953"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":147},"commonTop":["Hyperuricaemia","Diarrhoea","Upper respiratory tract infection","Hyperglycaemia","Dizziness"]}}